Browsing by Author "Arun K. Bind"

Now showing 1 - 2 of 2

Association of intronic variants (Apal and Bsml) of vitamin D receptor gene with uterine leiomyoma among North Indian women
(Elsevier B.V., 2025) Sonal Tiwari; Rakesh Kumar Gupta; Sakshi Agarwal; Amita Diwakar; Arun K. Bind; Pawan Kumar Dubey
Background: Understanding the genetic factors involved in the Uterine Leiomyoma (UL) development is crucial for exploring the complexities of UL disorders. This study aimed to examine genetic association between UL incidence and intronic polymorphisms of vitamin D receptor gene in north Indian population. Methodology: Total 200 subjects (100 healthy women and 100 with uterine leiomyomas) of age- and gender-matched control subjects, were genotyped for BsmI (rs1544410) and ApaI (rs7975232) polymorphisms in the VDR gene using TETRA ARMS PCR, followed by Sanger sequencing validation. Levels of VDR mRNA and vitamin D were also assessed through quantitative real-time PCR and ELISA respectively. The association of these variants with leiomyomas was analyzed, along with clinico-pathological (obesity) association. Results: ApaI revealed a significant association with UL, especially for the TG genotype (OR = 2.38; 95 % CI, 1.26–––4.51; p = 0.003). In a similar manner, ApaI is associated with an increased risk for UL with all three genetic models. Comparing VDR ApaI polymorphism between obese and non-obese patients revealed that AC genotype was significantly (OR = 3.71; 95 % CI, 1.53––9.11; p = 0.002) associated with a reduced risk of UL in non-obese patients. The expression of VDR mRNA was two times lower in patients with UL (p < 0.001), along with decreased serum vitamin D levels (p < 0.001). A significant association was also observed between VDR ApaI variant with reduced mRNA expression, vitamin D level and obesity. However, no associations were observed among Bsm1 VDR genotypes and ULs. Conclusion: This study found significant association between the VDR intronic ApaI polymorphism (rs7975232) and the incidence of UL. This VDR variant showed significant association with reduced VDR mRNA expression and serum vitamin D levels in UL patients. However, no significant association was observed between BsmI VDR polymorphism (rs1544410) and UL in North Indian women. © 2025 Elsevier B.V.
THPM (1,2,3,4-Tetrahydro pyrimidine) and Berberine Exhibit Synergistic Impact on Inhibition of Cell Migration and Colonization Through ROS-Mediated Apoptotic Pathways in the Breast Cancer Cells
(John Wiley and Sons Inc, 2025) Rakesh Kumar Gupta; Ambarish Priyadarshan; Sonal Tiwari; Yashvant Patel; Arun K. Bind; Garima Tripathi; Anima Tripathi; Abhijeet Kumar; Pawan Kumar Dubey
Breast cancer is one of the major causes of death in females worldwide. Considering the polypharmacological trend, small molecules like pyrimidine along with berberine, a bioactive anticancer agent may act as effective anticancer drugs having multiple targets with minimal side effects. However, it has never been tested. The present work discloses the efficacy of the combination of 1,2,3,4,-Tetrahydro pyrimidine (THPM) and Berberine (BBR) in inhibiting cancer progression in human breast cancer cell line, i.e., MCF-7. THPM were synthesized and characterized, and their anti-cancerous potential was evaluated by in silico study. The MCF-7 cells were exposed in vitro with THPM (200 µM), BBR (20 µM/ml) alone or in combination of THPM + BBR (200 µm + 20 µm/ml) for 24 h. Intracellular ROS, annexin-V staining, cell migration, colony formation assay, and gene expression analysis were performed. THPM and BBR both exhibited solid binding affinity against the BCL-2 protein. Interestingly, co-treatment of THPM + BBR significantly increased ROS level, annexin-V positive cells, the expression level of Bax, and Caspase-3 and inhibited migration and proliferation of MCF-7 cells. In conclusion, co-treatment of THPM + BBR exhibits a synergistic impact via inhibiting cell proliferation and inducing ROS-mediated apoptosis in MCF-7 cells suggesting that THPM and BBR could be used as novel therapeutic agents against breast cancer. © 2025 Wiley-VCH GmbH.